Comment on “AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis”

Yuze Wu

doi:10.1111/jgh.70748

September 15, 2026Journal of Gastroenterology and HepatologyOpen Access

Comment on “AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis”

View Full Paper

Ask AI

Bookmark

Share

Key Points

Provide commentary on the findings regarding how AKR1B10 suppresses ferroptosis to drive resistance to lenvatinib in hepatocellular carcinoma.
Conducted a critical evaluation and scientific commentary of published mechanistic research without generating or analyzing new primary datasets.
Highlights the regulatory role of AKR1B10 in preventing ferroptosis through modulation of the NQO1/GPX4 axis during lenvatinib exposure.
Identifies the therapeutic potential and mechanistic implications of targeting ferroptotic signaling pathways to overcome drug resistance in liver cancer.

Implication

Scientific commentary examines mechanisms of AKR1B10-mediated lenvatinib resistance in hepatocellular carcinoma, highlighting pathways regulating ferroptosis for targeted cancer therapies.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yuze Wu (2026) studied this question.

synapsesocial.com/papers/6aabb6b55f706d05830e53e5 https://doi.org/10.1111/jgh.70748

View Full Paper

Ask AI

Bookmark

Share

Comment on “AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis”

Key Points

Implication

Discussion

Cite This Study

Comment on “AKR1B10 Drives Lenvatinib Resistance in Hepatocellular Carcinoma by Suppressing Ferroptosis via NQO1/GPX4 Axis”

Key Points

Implication

Discussion

Cite This Study

Keep reading

Keep reading